EP3076949A4 - Analyse d'adn génomique, d'arn et de protéines dans des exosomes pour le diagnostic et la thérapie - Google Patents
Analyse d'adn génomique, d'arn et de protéines dans des exosomes pour le diagnostic et la thérapie Download PDFInfo
- Publication number
- EP3076949A4 EP3076949A4 EP14867768.5A EP14867768A EP3076949A4 EP 3076949 A4 EP3076949 A4 EP 3076949A4 EP 14867768 A EP14867768 A EP 14867768A EP 3076949 A4 EP3076949 A4 EP 3076949A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- theranosis
- exosomes
- rna
- diagnosis
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI201431412T SI3076949T1 (sl) | 2013-12-04 | 2014-12-04 | Postopek za izoliranje eksosomov, ki izvirajo iz rakavih celic |
| HRP20192131TT HRP20192131T1 (hr) | 2013-12-04 | 2014-12-04 | Metoda za izolaciju egzosoma izvedenih iz stanica karcinoma |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911863P | 2013-12-04 | 2013-12-04 | |
| PCT/US2014/068630 WO2015085096A1 (fr) | 2013-12-04 | 2014-12-04 | Analyse d'adn génomique, d'arn et de protéines dans des exosomes pour le diagnostic et la thérapie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3076949A1 EP3076949A1 (fr) | 2016-10-12 |
| EP3076949A4 true EP3076949A4 (fr) | 2017-11-22 |
| EP3076949B1 EP3076949B1 (fr) | 2019-09-04 |
Family
ID=53274132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14867768.5A Active EP3076949B1 (fr) | 2013-12-04 | 2014-12-04 | Procédé pour isoler des exoxomes dérivés des cellules cancères |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9921223B2 (fr) |
| EP (1) | EP3076949B1 (fr) |
| JP (3) | JP2017501694A (fr) |
| AU (3) | AU2014360344B2 (fr) |
| CA (1) | CA2936100A1 (fr) |
| DK (1) | DK3076949T3 (fr) |
| HR (1) | HRP20192131T1 (fr) |
| HU (1) | HUE046489T2 (fr) |
| LT (1) | LT3076949T (fr) |
| NZ (1) | NZ721720A (fr) |
| SI (1) | SI3076949T1 (fr) |
| WO (1) | WO2015085096A1 (fr) |
| ZA (1) | ZA201604468B (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| WO2006116362A2 (fr) | 2005-04-25 | 2006-11-02 | The Trustees Of Boston University | Substrats structures pour le profilage optique de surface |
| US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
| AU2013302799B2 (en) | 2012-08-13 | 2018-03-01 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| US11180812B2 (en) | 2012-08-17 | 2021-11-23 | Cornell University | Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease |
| CN105264092B (zh) | 2013-03-15 | 2019-02-22 | 得克萨斯州大学系统董事会 | 用于诊断和疗法的外来体中的miRNA生物发生 |
| JP2017501694A (ja) * | 2013-12-04 | 2017-01-19 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析 |
| US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
| CR20160307A (es) | 2013-12-20 | 2016-11-08 | Advanced Regen Medical Tech Llc | Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas |
| US10844436B2 (en) * | 2014-04-01 | 2020-11-24 | Cornell University | Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection |
| CA2962444C (fr) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cellules derivees de la cardiosphere et exosomes secretes par ces cellules dans le traitement d'une dystrophie musculaire |
| US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
| US11971402B2 (en) | 2015-04-24 | 2024-04-30 | Cornell University | Methods and reagents for determination and treatment of organotropic metastasis |
| US11339441B2 (en) * | 2015-05-12 | 2022-05-24 | The Research Foundation For The State University Of New York | Profiling chemically modified DNA/RNA units for disease and cancer diagnosis |
| WO2016201064A1 (fr) | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Texas System | Test de diagnostic pour le cancer à un stade précoce |
| US20180177727A1 (en) | 2015-06-10 | 2018-06-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
| CN114217058A (zh) | 2015-09-22 | 2022-03-22 | 波士顿大学董事会 | 纳米囊泡的多重表型分析 |
| GB201518466D0 (en) * | 2015-10-19 | 2015-12-02 | Cizzle Biotechnology Ltd | Use |
| EP3402543B1 (fr) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cellules dérivées de cardiosphères et exosomes sécrétés par ces cellules dans le traitement d'une insuffisance cardiaque à fraction d'éjection préservée |
| JP7033082B2 (ja) * | 2016-02-05 | 2022-03-09 | ナノビュー バイオサイエンシズ インコーポレイテッド | 表面マーカーを有するエキソソームの検出 |
| RU2018136151A (ru) * | 2016-03-15 | 2020-04-15 | Кодиак Байосайнсиз, Инк. | Терапевтические мембранные везикулы |
| EP3436081A4 (fr) | 2016-04-29 | 2019-07-24 | Advanced Regen Medical Technologies, LLC | Compositions de microarn, leurs procédés de préparation et d'utilisation |
| WO2017210652A1 (fr) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Exosomes dérivés de cdc pour le traitement des tachyarythmies ventriculaires |
| WO2017223186A1 (fr) * | 2016-06-21 | 2017-12-28 | Nant Holdings Ip, Llc | Traitement du cancer guidé par exosome |
| CN106124282B (zh) | 2016-07-26 | 2019-07-16 | 广州海力特生物科技有限公司 | 一种叠层离心过滤分离提取外泌体的方法 |
| US20180067121A1 (en) * | 2016-09-06 | 2018-03-08 | Nanoco Technologies Ltd. | Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| CN110650728B (zh) * | 2017-03-21 | 2023-06-23 | 埃索普罗瑟医疗有限公司 | 含有用于治疗的肿瘤抑制蛋白的天然细胞衍生的囊泡 |
| GB2560897A (en) | 2017-03-23 | 2018-10-03 | Lotvall Jan | Tissue-derived extracellular vesicles and their use as diagnostics |
| EP4699658A2 (fr) | 2017-04-19 | 2026-02-25 | Cedars-Sinai Medical Center | Méthodes et compositions pour le traitement de la dystrophie musculaire squelettique |
| CN107338306A (zh) * | 2017-07-23 | 2017-11-10 | 嘉兴允英医学检验有限公司 | 一种用于GPC1mRNA表达检测的试剂盒 |
| JP2020529477A (ja) * | 2017-08-04 | 2020-10-08 | シーダーズ—シナイ メディカル センター | がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞 |
| GB2574785A (en) | 2017-09-15 | 2019-12-25 | Jan Loetvall | Method and system for identifying membrane proteins on extracellular vesicles |
| WO2019094692A2 (fr) | 2017-11-09 | 2019-05-16 | The Trustees Of The University Of Pennsylvania | Protéines vésiculaires extracellulaires et leur utilisation pour le diagnostic du cancer, la prédiction de la réponse à une thérapie et le traitement |
| WO2019109077A1 (fr) | 2017-12-01 | 2019-06-06 | Cornell University | Nanoparticules et sous-ensembles d'exosomes distincts pour la détection et le traitement du cancer |
| CA3084821A1 (fr) | 2017-12-15 | 2019-06-20 | Board Of Regents, The University Of Texas System | Methodes et compositions pour le traitement du cancer utilisant des exosomes associes a l'edition genique |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| AU2018394238A1 (en) * | 2017-12-28 | 2020-06-18 | Lonza Sales Ag | Exosomes for immuno-oncology and anti-inflammatory therapy |
| US10717981B2 (en) | 2018-01-18 | 2020-07-21 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
| US12146137B2 (en) | 2018-02-05 | 2024-11-19 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and Y-RNAS |
| US12241888B2 (en) | 2018-03-14 | 2025-03-04 | Children's Medical Center Corporation | Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof |
| JP7813099B2 (ja) * | 2018-03-28 | 2026-02-12 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 治療用物質を標的送達するためのエキソソームの使用法 |
| EP3775258A4 (fr) * | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | Identification d'altérations épigénétiques dans de l'adn isolé à partir d'exosomes |
| CN112236130A (zh) * | 2018-04-09 | 2021-01-15 | 得克萨斯州大学系统董事会 | 使用外排体对癌基因的治疗性靶向 |
| EP3788150A4 (fr) * | 2018-05-04 | 2022-01-26 | Sigma-Aldrich Co. LLC | Production de protéines recombinées présentant des taux réduits de protéines de cellules hôtes |
| EP3803332A1 (fr) | 2018-06-01 | 2021-04-14 | NanoView Biosciences, Inc. | Compositions, systèmes et procédés de détection améliorée sans marqueur et à base de fluorescence de nanoparticules |
| IL269897B2 (en) | 2018-11-15 | 2023-08-01 | Sternum Ltd | Implementing control flow correctness verification in code intermediate files |
| US11766484B2 (en) | 2019-01-03 | 2023-09-26 | International Business Machines Corporation | Exosome vessels for delivery of molecular cargo |
| WO2020146390A1 (fr) | 2019-01-09 | 2020-07-16 | Exocure Biosciences, Inc. | Vésicules dérivées de bactéries et leurs utilisations |
| US20220113313A1 (en) * | 2019-02-01 | 2022-04-14 | NanoView Biosciences, Inc. | Systems and methods for vesicle cargo labeling and detection |
| AU2020218358A1 (en) * | 2019-02-08 | 2021-08-26 | Board Of Regents, The University Of Texas System | Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes |
| CN114080232A (zh) * | 2019-03-21 | 2022-02-22 | 科迪亚克生物科学公司 | 用于疫苗递送的细胞外囊泡 |
| WO2020219699A1 (fr) * | 2019-04-23 | 2020-10-29 | Children's Medical Center Corporation | Utilisation d'inhibiteurs de la gtpase rab7 (rab7) pour augmenter la perméabilité de la barrière hémato-encéphalique (bhe) |
| EP4013392B1 (fr) | 2019-09-13 | 2026-04-29 | Exocure Sweden AB | Utilisation de nanovésicules fantômes en tant qu'agents thérapeutiques |
| JP7462452B2 (ja) * | 2020-03-27 | 2024-04-05 | 株式会社日立製作所 | 培養細胞の分化レベルを評価するための評価装置および評価方法、並びに自動細胞培養システム |
| CN112698033A (zh) * | 2020-12-09 | 2021-04-23 | 复旦大学附属中山医院 | 一种血源性外泌体her2的检测方法及其应用 |
| US20230340606A1 (en) * | 2021-09-09 | 2023-10-26 | The Regents Of The University Of California | Extracellular repetitive rna biomarkers of mutant kras cancers |
| WO2023081099A1 (fr) * | 2021-11-02 | 2023-05-11 | Daniel Kim | Signatures de l'arn extracellulaire dans les cancers kras(g12c) mutants |
| WO2023210644A1 (fr) * | 2022-04-26 | 2023-11-02 | 国立大学法人東京大学 | Procédé d'isolement et de concentration d'un groupe de vésicules extracellulaires dérivé d'une cellule cancéreuse, procédé d'analyse, procédé de sélection de médicament, kit et agent anticancéreux |
| US20250290919A1 (en) * | 2022-05-06 | 2025-09-18 | The Trustees Of The University Of Pennsylvania | Ultrasensitive single extracellular vesicle detection using high throughput droplet digital enzyme-linked immunosorbent assay |
| WO2024047441A1 (fr) * | 2022-09-01 | 2024-03-07 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud | Méthode de surveillance de la charge tumorale chez des sujets au cours d'une intervention thérapeutique |
| WO2024073671A1 (fr) * | 2022-09-30 | 2024-04-04 | Foundation Medicine, Inc. | Systèmes et procédés de traitement de données clinico-génomiques |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196426A1 (en) * | 2008-02-01 | 2010-08-05 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of medical diseases and conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US20030064949A1 (en) * | 1998-02-17 | 2003-04-03 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| KR100519384B1 (ko) | 2002-08-13 | 2005-10-06 | (주)누백스 | 유전자 이입을 이용한 엑소좀의 제조방법 및 상기 엑소좀의 용도 |
| US20120196285A1 (en) * | 2011-01-31 | 2012-08-02 | Esoterix Genetic Laboratories, Llc | Methods for Enriching Microparticles or Nucleic Acids Using Binding Molecules |
| US9777042B2 (en) * | 2011-12-15 | 2017-10-03 | Morehouse School Of Medicine | Method of purifying HIV/SIV Nef from exosomal fusion proteins |
| US9309559B2 (en) * | 2013-04-15 | 2016-04-12 | Albert Einstein College Of Medicine, Inc. | Simultaneous extraction of DNA and RNA from FFPE tissues |
| JP2017501694A (ja) * | 2013-12-04 | 2017-01-19 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析 |
-
2014
- 2014-12-04 JP JP2016536918A patent/JP2017501694A/ja not_active Ceased
- 2014-12-04 LT LT14867768T patent/LT3076949T/lt unknown
- 2014-12-04 WO PCT/US2014/068630 patent/WO2015085096A1/fr not_active Ceased
- 2014-12-04 HU HUE14867768A patent/HUE046489T2/hu unknown
- 2014-12-04 HR HRP20192131TT patent/HRP20192131T1/hr unknown
- 2014-12-04 EP EP14867768.5A patent/EP3076949B1/fr active Active
- 2014-12-04 CA CA2936100A patent/CA2936100A1/fr active Pending
- 2014-12-04 NZ NZ721720A patent/NZ721720A/en not_active IP Right Cessation
- 2014-12-04 AU AU2014360344A patent/AU2014360344B2/en not_active Ceased
- 2014-12-04 US US15/101,857 patent/US9921223B2/en active Active
- 2014-12-04 DK DK14867768T patent/DK3076949T3/da active
- 2014-12-04 SI SI201431412T patent/SI3076949T1/sl unknown
-
2016
- 2016-06-30 ZA ZA2016/04468A patent/ZA201604468B/en unknown
-
2017
- 2017-11-01 US US15/801,269 patent/US10598665B2/en active Active
-
2019
- 2019-01-30 AU AU2019200573A patent/AU2019200573A1/en not_active Abandoned
- 2019-02-25 AU AU2019201290A patent/AU2019201290A1/en not_active Withdrawn
- 2019-08-13 JP JP2019148579A patent/JP2019198327A/ja not_active Withdrawn
-
2020
- 2020-03-04 US US16/809,300 patent/US20200200755A1/en not_active Abandoned
-
2021
- 2021-07-02 JP JP2021110830A patent/JP7138372B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196426A1 (en) * | 2008-02-01 | 2010-08-05 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of medical diseases and conditions |
Non-Patent Citations (12)
| Title |
|---|
| C. LAU ET AL: "Role of Pancreatic Cancer-derived Exosomes in Salivary Biomarker Development", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 37, 23 July 2013 (2013-07-23), US, pages 26888 - 26897, XP055371685, ISSN: 0021-9258, DOI: 10.1074/jbc.M113.452458 * |
| CHANG LAU ET AL: "Supplemental information for Role of Pancreatic Cancer-derived Exosomes in Salivary Biomarker Development", 23 July 2013 (2013-07-23), XP055386650, Retrieved from the Internet <URL:http://www.jbc.org/content/suppl/2013/08/01/M113.452458.DC1/jbc.M113.452458-1.pdf> [retrieved on 20170629] * |
| FRANCESCA PROPERZI ET AL: "Exosomes: the future of biomarkers in medicine", BIOMARKERS IN MEDICINE, vol. 7, no. 5, 1 October 2013 (2013-10-01), UK, pages 769 - 778, XP055386446, ISSN: 1752-0363, DOI: 10.2217/bmm.13.63 * |
| GÖRAN K. RONQUIST ET AL: "Prostasomal DNA characterization and transfer into human sperm", MOLECULAR REPRODUCTION AND DEVELOPMENT, vol. 78, no. 7, 2 June 2011 (2011-06-02), NEW YORK, NY, US, pages 467 - 476, XP055386184, ISSN: 1040-452X, DOI: 10.1002/mrd.21327 * |
| GÖRAN K. RONQUIST ET AL: "Prostasomes are heterogeneous regarding size and appearance but affiliated to one DNA-containing exosome family", PROSTATE., vol. 72, no. 16, 26 April 2012 (2012-04-26), US, pages 1736 - 1745, XP055412538, ISSN: 0270-4137, DOI: 10.1002/pros.22526 * |
| JIN CAI ET AL: "Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells", JOURNAL OF MOLECULAR CELL BIOLOGY, vol. 5, no. 4, 11 April 2013 (2013-04-11), pages 227 - 238, XP055386088, ISSN: 1674-2788, DOI: 10.1093/jmcb/mjt011 * |
| K. GÖRAN RONQUIST ET AL: "Human prostasomes contain chromosomal DNA", PROSTATE., vol. 69, no. 7, 15 May 2009 (2009-05-15), US, pages 737 - 743, XP055386181, ISSN: 0270-4137, DOI: 10.1002/pros.20921 * |
| LI JIANGHONG ET AL: "Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 9, no. 1, 20 July 2009 (2009-07-20), pages 244, XP021057622, ISSN: 1471-2407, DOI: 10.1186/1471-2407-9-244 * |
| LOGOZZI MARIANTONIA ET AL: "High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. e5219", PLOS ONE,, vol. 4, no. 4, 1 April 2009 (2009-04-01), pages 1 - 10, XP002527287, DOI: 10.1371/JOURNAL.PONE.0005219 * |
| MICHELE GUESCINI ET AL: "Astrocytes and Glioblastoma cells release exosomes carrying mtDNA", JOURNAL OF NEURAL TRANSMISSION ; BASIC NEUROSCIENCES, GENETICS AND IMMUNOLOGY, PARKINSON'S DISEASE AND ALLIED CONDITIONS, ALZHEIMER'S DISEASE AND ADOLESCENT PSYCHIATRY RELATED DISORDERS, BIOLOGICAL PSYCHIATRY, BIOLOGICAL CHILD AND ADOLESCENT PSYCHIAT, vol. 117, no. 1, 13 August 2009 (2009-08-13), pages 1 - 4, XP019783123, ISSN: 1435-1463 * |
| See also references of WO2015085096A1 * |
| TAYLOR D D ET AL: "MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 110, no. 1, 1 July 2008 (2008-07-01), pages 13 - 21, XP022795052, ISSN: 0090-8258, [retrieved on 20080625], DOI: 10.1016/J.YGYNO.2008.04.033 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200200755A1 (en) | 2020-06-25 |
| US10598665B2 (en) | 2020-03-24 |
| HUE046489T2 (hu) | 2020-03-30 |
| JP2021177760A (ja) | 2021-11-18 |
| AU2014360344A1 (en) | 2016-07-14 |
| LT3076949T (lt) | 2019-12-10 |
| US9921223B2 (en) | 2018-03-20 |
| AU2019200573A1 (en) | 2019-02-21 |
| SI3076949T1 (sl) | 2020-01-31 |
| WO2015085096A1 (fr) | 2015-06-11 |
| ZA201604468B (en) | 2024-01-31 |
| AU2014360344B2 (en) | 2018-11-29 |
| CA2936100A1 (fr) | 2015-06-11 |
| DK3076949T3 (da) | 2019-11-25 |
| NZ721720A (en) | 2022-04-29 |
| JP7138372B2 (ja) | 2022-09-16 |
| US20170059572A1 (en) | 2017-03-02 |
| US20180045728A1 (en) | 2018-02-15 |
| HRP20192131T1 (hr) | 2020-02-21 |
| EP3076949B1 (fr) | 2019-09-04 |
| JP2017501694A (ja) | 2017-01-19 |
| AU2019201290A1 (en) | 2019-03-14 |
| JP2019198327A (ja) | 2019-11-21 |
| EP3076949A1 (fr) | 2016-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3076949A4 (fr) | Analyse d'adn génomique, d'arn et de protéines dans des exosomes pour le diagnostic et la thérapie | |
| SG11201500371VA (en) | Methods of detecting dna, rna and protein in biological samples | |
| IL257714B (en) | Systems and methods for the analysis of multiple analytes | |
| EP3091074A4 (fr) | Système d'analyse des répertoires des récepteurs des lymphocytes t et des lymphocytes b et leur utilisation dans le traitement et le diagnostic | |
| EP2994543A4 (fr) | Dispositif pour la préparation et l'analyse d'acides nucléiques | |
| EP3080300A4 (fr) | Systèmes et procédés d'analyse et d'informatique biologiques | |
| EP3027775A4 (fr) | Séquençage d'adn et analyse de l'épigénome | |
| BR112016010095A2 (pt) | ácidos nucleicos de célula livre para a ánalise de microbioma humano e componentes do mesmos. | |
| SG11201506660RA (en) | Methods, compositions, and kits for nucleic acid analysis | |
| EP3080289A4 (fr) | Molécules d'acides nucléiques modifiés et leurs utilisations | |
| EP2856120A4 (fr) | Système et procédé d'analyse de fluides biologiques | |
| SG11201405785WA (en) | Systems and methods for biological analysis | |
| IL239926A0 (en) | A process for detecting changes in DNA and protein binding through manipulation of a single molecule | |
| EP3007824A4 (fr) | Système et procédés de collecte d'échantillons de fluide préférentiels pour arn/protéines/adn | |
| EP3087202A4 (fr) | Procédé et kit de détection d'acide nucléique | |
| EP2992083A4 (fr) | Analyse de l'adn | |
| EP2845003A4 (fr) | Système et technique de mesure d'analyte améliorés | |
| PT3065764T (pt) | Análogo de minigastrina, em particular para uso no diagnóstico e/ou tratamento de tumor positivo ao recetor cck2 | |
| EP2978862A4 (fr) | Compositions doubles sonde:anti-sonde pour la détection d'adn et d'arn | |
| SG11201500649UA (en) | Nucleic acid analysis apparatus, microchip for nucleic acid analysis, and method for mounting microchip in nucleic acid analysis apparatus | |
| EP2873963B8 (fr) | Système d'analyse centrifuge et procédé d'analyse de celui-ci | |
| EP2979077A4 (fr) | Traitement d'un échantillon biologique | |
| EP3021740A4 (fr) | Système et procédé d'analyse de la tension artérielle | |
| EP2909589A4 (fr) | Appareil et procédés d'analyse ultrasonore d'échantillon biologique | |
| EP2872652A4 (fr) | Dispositifs et méthodes de préparation et d'analyse d'acides nucléiques |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160630 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20170711BHEP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602014053187 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0009000000 Ipc: G01N0033574000 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1227707 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20171019 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/574 20060101AFI20171013BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20180820 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20190318 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1176089 Country of ref document: AT Kind code of ref document: T Effective date: 20190915 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014053187 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20191118 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20192131T Country of ref document: HR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER AND CIE S.A., CH |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: NO Ref legal event code: T2 Effective date: 20190904 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191204 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20192131T Country of ref document: HR Payment date: 20191127 Year of fee payment: 6 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20192131 Country of ref document: HR |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191205 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1176089 Country of ref document: AT Kind code of ref document: T Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E046489 Country of ref document: HU |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200106 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014053187 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20200605 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20192131 Country of ref document: HR Payment date: 20201116 Year of fee payment: 7 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20192131 Country of ref document: HR Payment date: 20211202 Year of fee payment: 8 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190904 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20192131 Country of ref document: HR Payment date: 20221201 Year of fee payment: 9 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230516 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20192131 Country of ref document: HR Payment date: 20231130 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231130 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MC Payment date: 20231213 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20231215 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20231130 Year of fee payment: 10 Ref country code: SE Payment date: 20231213 Year of fee payment: 10 Ref country code: NO Payment date: 20231212 Year of fee payment: 10 Ref country code: NL Payment date: 20231215 Year of fee payment: 10 Ref country code: MT Payment date: 20231219 Year of fee payment: 10 Ref country code: LV Payment date: 20231205 Year of fee payment: 10 Ref country code: LU Payment date: 20231214 Year of fee payment: 10 Ref country code: LT Payment date: 20231130 Year of fee payment: 10 Ref country code: IE Payment date: 20231211 Year of fee payment: 10 Ref country code: HU Payment date: 20231213 Year of fee payment: 10 Ref country code: HR Payment date: 20231130 Year of fee payment: 10 Ref country code: FR Payment date: 20231212 Year of fee payment: 10 Ref country code: FI Payment date: 20231219 Year of fee payment: 10 Ref country code: DK Payment date: 20231214 Year of fee payment: 10 Ref country code: DE Payment date: 20231205 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20231219 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: MK Payment date: 20231130 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240102 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AL Payment date: 20231221 Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: PBON Ref document number: P20192131 Country of ref document: HR Effective date: 20241204 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM4D Effective date: 20241204 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602014053187 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20241231 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20250101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241205 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20241231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20250701 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241204 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20241231 |